Indications -- Depression Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Depression

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: scaram(o)uche who started this subject	8/9/2003 11:54:19 PM
From: scaram(o)uche	of 21

Message 19193794 Name / company Class Clinical trial status / attributes elzasonan / Pfizer serotonin autoreceptor antagonist midstage / potentially faster-acting CP 122,721 / Pfizer substance P antagonist late stage / may help those not responding to other antidepressants aprepitant / Merck substance P antagonist late stage / may cause less sexual dysfunction Cymbalta / Eli Lilly dual reuptake inhibitor completed / may be more potent than SSRIs AR-A2 / AstraZeneca serotonin 1b antagonist early stage / novel class; may reduce anxiety AZD-1134 / AstraZeneca serotonin 1b antagonist early stage / novel class; may reduce anxiety GSK 352162 / GlaxoSmithKline second-generation noradrenaline/ dopamine reuptake inhibitor early stage / may not cause any sexual dysfunction GSK 679769; 597599/ GlaxoSmithKline neurokinin-1 antagonists early stage/ may reduce nausea and sexual dysfunction

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext